Vnitr Lek 2009, 55(3):242-252

Thrombophilic states: their relevance in prevention and treatment of venous thromboembolism

H. Poul*, P. Kessler
Oddělení hematologie a transfuziologie nemocnice Pelhřimov, přednosta prim. MUDr. Petr Kessler

Thrombophilic states are congenital or acquired haemostasis disorders with pathophysiological and statistical association to increased risk of thrombosis. Venous thromboembolism is their most important clinical manifestation. More than 50% of patients with unprovoked thrombosis have one of the known thrombophilias. Patients with congenital thrombophilias have, in comparison to those without thrombophilia, increased risk of the first thromboembolic event, while the impact of genetically defined thrombophilic states on recurrence is less evident. The risk of recurrence in patients with idiopathic thrombosis is 7-10% per year even in the absence of a known thrombophilia. The risk of recurrent event is affected by a range of other factors (persisting or undiagnosed precipitating factor, proximal thrombosis and pulmonary embolism, incomplete recanalization, vessel thrombosis, presence of some thrombophilias, high D-dimmer levels after anticoagulant therapy discontinuation). Identification and subsequent monitoring of these factors is crucial for optimal selection of the treatment to be used as a secondary prevention of venous thromboembolism and its duration. Primary prevention of venous thromboembolism requires good knowledge of general precipitating factors as well as the specific risks in each patient and thus also means an early investigation of thrombophilic states in patients who will benefit from their identification and in whom there is at least medium probability of their identification. Universal long-term prevention in so far asymptomatic carriers of congenital thrombophilias is not indicated considering the potential complications of anticoagulant treatment. Women with thrombophilic disorders have an increased risk of thromboembolic event if using hormonal contraception and during pregnancy. They also have an increased risk of pregnancy complications related to placental circulation blood flow disorders.

Keywords: thrombophilia; venous thromboembolism; thrombosis prophylaxis; recurrent thrombosis; gravidity

Received: January 30, 2009; Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Poul H, Kessler P. Thrombophilic states: their relevance in prevention and treatment of venous thromboembolism. Vnitr Lek. 2009;55(3):242-252.
Download citation

References

  1. Ageno W, Squizzato A, Garcia D et al. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006; 32: 651-658. Go to original source... Go to PubMed...
  2. Kearon C, Julian JA, Kovacs MJ et al. ELATE Investigators. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 2008; 112: 4432-4436. Go to original source... Go to PubMed...
  3. Zöller B, García de Frutos P, Hillarp A et al. Thrombophilia as a multigenic disease. Haematologica 1999; 84: 59-70. Go to PubMed...
  4. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67. Go to original source... Go to PubMed...
  5. den HeijerM, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762. Go to original source... Go to PubMed...
  6. Heijboer H, Brandjes DP, Büller HR et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516. Go to original source... Go to PubMed...
  7. Koster T, Rosendaal FR, de Ronde H et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Trombophilia Study. Lancet 1993; 342: 1503-1506. Go to original source... Go to PubMed...
  8. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996. Go to original source... Go to PubMed...
  9. Pabinger I, Brücker S, Kyrle PA et al. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis 1992; 3: 547-553. Go to original source...
  10. Tait RC, Walker ID, Perry DJ et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112. Go to original source... Go to PubMed...
  11. Tait RC, Walker ID, Reitsma PH et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87-93. Go to original source... Go to PubMed...
  12. Nordström M, Lindblad B, Bergqvist D et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-160. Go to original source... Go to PubMed...
  13. Martinelli I, Mannucci PM, De Stefano V et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358. Go to original source...
  14. Simioni P, Sanson BJ, Prandoni P et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202. Go to original source... Go to PubMed...
  15. Middeldorp S, Henkens CM, Koopman MM et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128: 15-20. Go to original source... Go to PubMed...
  16. Poort SR, Rosendaal FR, Reitsma PH et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703. Go to original source...
  17. Blom JW, Doggen CJ, Osanto S et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722. Go to original source... Go to PubMed...
  18. Koster T, Blann AD, Briët E et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155. Go to original source... Go to PubMed...
  19. Kraaijenhagen RA, in't Anker PS, Koopman MM et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9. Go to original source... Go to PubMed...
  20. van Hylckama Vlieg A, van der Linden IK, Bertina RM et al. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 3678-3682. Go to original source...
  21. Meijers JCM. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Eng J Med 2000; 342: 696-701. Go to original source... Go to PubMed...
  22. den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80: 874-877. Go to original source... Go to PubMed...
  23. Wahl DG, Guillemin F, de Maistre E et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7: 15-22. Go to original source... Go to PubMed...
  24. Christiaens L. Idiopathic venous thromboembolic disease. Risk factors for recurrence in 2006. Arch Mal Coeur Vaiss 2007; 100: 133-138. Go to PubMed...
  25. Linnemann B, Zgouras D, Schindewolf M et al. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagul Fibrinolysis 2008; 19: 159-165. Go to original source... Go to PubMed...
  26. Dalen JE. Should patients with venous thromboembolism be screened for thrombophilia? Am J Med 2008; 121: 458-463. Go to original source... Go to PubMed...
  27. Stevenson MD, Rawdin A, Papaioannou D. Thrombophilia testing in people with venous thromboembolism: systematic review and cost-effectiveness analysis. Health Technol Assess 2009; 13: 1-91. Go to original source...
  28. Sternitzky R, Hochauf S, Schellong SM. Secondary prophylaxis of venous thromboembolism. Hamostaseologie 2007; 27: 32-40. Go to original source... Go to PubMed...
  29. Prandoni P, Noventa F, Ghirarduzzi A et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199-205. Go to original source... Go to PubMed...
  30. Baglin T, Luddington R, Brown K et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526. Go to original source... Go to PubMed...
  31. Palareti G, Legnani C, Cosmi B et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-318. Go to original source... Go to PubMed...
  32. Lindmarker P, Schulman S, Sten-Linder M et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999; 81: 684-689. Go to original source... Go to PubMed...
  33. Simioni P, Prandoni P, Lensing AW et al. The risk of recurrent venous thromboembolism in patients with an Arg506→ Gln mutation in the gene for factor V (factor V Leiden). N Eng J Med 1997; 336: 399-403. Go to original source... Go to PubMed...
  34. Ridker PM. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2802. Go to original source... Go to PubMed...
  35. Eichinger S, Weltermann A, Mannhalter C et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002; 162: 2357-2360. Go to original source... Go to PubMed...
  36. Kovac M, Mikovic D, Antonijevic N et al. FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population. J Thromb Thrombolysis 2008; 25: 284-287. Go to original source... Go to PubMed...
  37. Marchiori A, Mosena L, Prins MH et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-1114. Go to original source... Go to PubMed...
  38. Eichinger S, Minar E, Hirschl M et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999; 81: 14-17. Go to original source... Go to PubMed...
  39. De Stefano V, Martinelli I, Mannucci PM et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 2001; 113: 630-635. Go to original source... Go to PubMed...
  40. Miles JS, Miletich JP, Goldhaber SZ et al. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 2001; 37: 215-218. Go to original source... Go to PubMed...
  41. Eichinger S, Stümpflen A, Hirschl M et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-569. Go to PubMed...
  42. den Heijer M, Blom HJ, Gerrits WB et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-885. Go to original source... Go to PubMed...
  43. Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Eng J Med 2000; 343: 457-462. Go to original source... Go to PubMed...
  44. Legnani C, Cini M, Cosmi B et al. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. Haematologica 2004; 89: 1347-1351. Go to PubMed...
  45. Eischer L, Gartner V, Schulman S et al. For the AUREC-FVIII investigators (as listed in acknowledgements). 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Ann Hematol 2008. [Epub ahead of print]. Go to original source... Go to PubMed...
  46. Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost 1996; 75: 859. Go to original source...
  47. Rance A, Emmerich J, Fiessinger JN. Anticardiolipin antibodies and recurrent thromboembolism. Thromb Haemost 1997; 77: 221-222. Go to original source... Go to PubMed...
  48. Schulman S, Svenungsson E, Grangvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104: 332-338. Go to original source... Go to PubMed...
  49. Bounameaux H, Perrier A. Duration of anticoagulation therapy for venous thromboembolism. Hematology Am Soc Hematol Educ Program 2008; 2008: 252-258. Go to original source... Go to PubMed...
  50. Cosmi B, Legnani C, Cini M et al. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Res 2008; 122: 610-617. Go to original source... Go to PubMed...
  51. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl 3): 338S-400S. Go to original source... Go to PubMed...
  52. White RH, Zhou H, Romano PS. Incidence of symptomatic venous tromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90: 446-455. Go to original source... Go to PubMed...
  53. Bates SM, Greer IA, Pabinger I et al. American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl 6): 844S-886S. Go to original source...
  54. Heit JA, Melton LJ 3rd, Lohse CM et al. Incidence of venous tromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001; 76: 1102-1110. Go to original source... Go to PubMed...
  55. Heit JA, O'Fallon WM, Petterson TM et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-1248. Go to original source... Go to PubMed...
  56. Alikhan R, Cohen AT, Combe S et al. Risk factors for venous tromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963-968. Go to original source... Go to PubMed...
  57. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case control study. Arch Intern Med 2000; 160: 809-815. Go to original source... Go to PubMed...
  58. Heit JA, Petterson TM, Bailey KR et al. The influence of tumor site on venous tromboembolism risk among cancer patients: a population-based study (Abstract 2596). Blood 2004; 104: 711a. Go to original source...
  59. Levitan N, Dowlati A, Remick SC. Rates of initial and recurrent tromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-291. Go to original source... Go to PubMed...
  60. Palareti G, Cosmi B. Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004; 11: 192-197. Go to PubMed...
  61. Kearon C, Gent M, Hirsh J et al. A comparsion of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous tromboembolism. N Engl J Med 1999; 340: 901-907. Go to original source... Go to PubMed...
  62. Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Eng J Med 2001; 345: 165-169. Go to original source... Go to PubMed...
  63. Baglin T, Luddington R, Brown K et al. Incidence of recurrent venous tromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526. Go to original source... Go to PubMed...
  64. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-774. Go to original source... Go to PubMed...
  65. Cushman M, Tsai AW, White RH et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19-25. Go to original source... Go to PubMed...
  66. Heit JA, Mohr DN, Silverstein MD et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-768. Go to original source... Go to PubMed...
  67. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous tromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488. Go to original source... Go to PubMed...
  68. Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7. Go to original source... Go to PubMed...
  69. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis 2008; 25: 37-44. Go to original source... Go to PubMed...
  70. Piovella F, Crippa L, Barone M et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002; 87: 515-522. Go to PubMed...
  71. Prandoni P, Lensing AW, Prins MH et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-960. Go to original source... Go to PubMed...
  72. Eichinger S, Minar E, Bialonczyk C et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290: 1071-1074. Go to original source... Go to PubMed...
  73. Verhovsek M, Douketis JD, Yi Q et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149: 481-490. Go to original source... Go to PubMed...
  74. Palareti G, Cosmi B, Legnani C et al. PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789. Go to original source... Go to PubMed...
  75. Rey E, Kahn SR, David M et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-908. Go to original source... Go to PubMed...
  76. Gris JC, Mercier E, Quéré I et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-3699. Go to original source... Go to PubMed...
  77. Clark P, Brennand J, Conkie JA et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-1170. Go to original source... Go to PubMed...
  78. Stirling Y, Woolf L, North WR et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-182. Go to original source... Go to PubMed...
  79. Bonnar J, McNicol GP, Douglas AS. Fibrinolytic enzyme system and pregnancy. Br Med J 1969; 3: 387-389. Go to original source... Go to PubMed...
  80. Beller FK, Ebert C. The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. Eur J Obstet Gynecol Reprod Biol 1982; 13: 177-197. Go to original source... Go to PubMed...
  81. McColl MD, Ramsay JE, Tait RC et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-1188. Go to original source... Go to PubMed...
  82. Lindqvist P, Dahlbäck B, Marŝál K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595-599. Go to original source... Go to PubMed...
  83. Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001; 86: 104-111. Go to original source... Go to PubMed...
  84. Martinelli I, Legnani C, Bucciarelli P et al. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86: 800-803. Go to original source... Go to PubMed...
  85. Brill-Edwards P, Ginsberg JS, Gent M et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343: 1439-1444. Go to original source... Go to PubMed...
  86. Bokarewa MI, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-478. Go to original source... Go to PubMed...
  87. Pomp ER, Lenselink AM, Rosendaal FR et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632-637. Go to original source... Go to PubMed...
  88. Martinelli I, De Stefano V, Taioli E et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87: 791-795. Go to original source... Go to PubMed...
  89. Blanco-Molina A, Trujillo-Santos J, Criado J et al. RIETE Investigators. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost 2007; 97: 186-190. Go to original source... Go to PubMed...
  90. Wu O, Robertson L, Twaddle S et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006; 10: 1-110. Go to original source... Go to PubMed...
  91. Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Eng J Med 2000; 342: 374-380. Go to original source... Go to PubMed...
  92. Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003; 90: 77-85. Go to original source... Go to PubMed...
  93. Hallak M, Senderowicz J, Cassel A et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynec 1997; 176: 889-893. Go to original source... Go to PubMed...
  94. Hirsch DR, Mikkola KM, Marks PW et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996; 131: 1145-1148. Go to original source... Go to PubMed...
  95. Lensen RP, Bertina RM, de Ronde H et al. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000; 83: 817-821. Go to original source... Go to PubMed...
  96. Meglic L, Stegnar M, Milanez T et al. Factor V Leiden, prothrombin 20210G-A, methylentetrahydrofolate reductase 677C-T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous tromboembolism. Eur J Obstet Gynecol Reprod Biol 2003; 111: 157-163. Go to original source... Go to PubMed...
  97. Ogunyemi D, Cuellar F, Ku W et al. Association between inherited trombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous tromboembolism in pregnancy. Am J Perinatol 2003; 20: 17-24. Go to original source... Go to PubMed...
  98. Nelen WL, Blom HJ, Steegers EA et al. Hyperhomocysteinaemi a and recurrent early pregnancy loss: a meta analysis. Fertil Steril 2000; 74: 1196-1199. Go to original source... Go to PubMed...
  99. Lindqvist PG, Svensson PJ, Marsaál K et al. Activated protein C resistance (FV: Q506) and pregnancy. Thromb Haemost 1999; 81: 532-537. Go to original source... Go to PubMed...
  100. Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. BMJ 1998; 316: 95-99. Go to original source... Go to PubMed...
  101. Robertson L, Wu O, Langhorne P et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196. Go to original source... Go to PubMed...
  102. Bauersachs RM, Dudenhausen J, Faridi A et al. EThIG Investigators. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98: 1237-1245. Go to original source... Go to PubMed...
  103. Lindhoff-Last E, Luxembourg B. Evidence-based indications for thrombophilia screening. Vasa 2008; 37: 19-30. Go to original source... Go to PubMed...
  104. Simioni P. Who should be tested for thrombophilia? Curr Opin Hematol 2006; 13: 337-343. Go to original source... Go to PubMed...
  105. Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden: cost-effectiveness analysis. Thromb Haemost 2000; 84: 752-757. Go to original source... Go to PubMed...
  106. DiNisio M, Peters LW, Middeldorp S. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. Protocol for a Cochrane Review. The Cochrane Library 2004. Go to original source...
  107. Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - No. J Thromb Haemost 2003; 1: 2073-2074. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.